Anzeige
Meldung des Tages: Mit Graphen gegen jede Abwehr — Die Zukunft der Drohnen ist da

United Community Bank News

Aktie
WKN:  A1JB5Q ISIN:  US90984P3038 US-Symbol:  UCB Land:  USA
28,40 €
+0,00 €
0,00%
16:39:34 Uhr
Depot/Watchlist
Marktkapitalisierung *
-
Streubesitz
16,47%
KGV
14,36
Dividende
0,85 EUR
Dividendenrendite
3,25%
Index-Zuordnung
-

United Community Banks News

28.04.26 - PR Newswire
United Community Chief Financial Officer Jefferson Harralson to Retire After Nearly a Decade of Dedicated Service
United Community Chief Financial Officer Jefferson Harralson to Retire After Nearly a Decade of Dedicated Service PR Newswire
20.04.26 - PR Newswire
Myasthenia Gravis Foundation of America Launches MGFA Food Support Program to Advance Nutrition Access and Health Equity for Individuals with Myasthenia Gravis
Myasthenia Gravis Foundation of America Launches MGFA Food Support Program to Advance Nutrition Access and Health Equity for Individuals with Myasthenia Gravis PR Newswire
17.04.26 - PR Newswire
UCB to acquire Neurona Therapeutics, advancing its innovative leadership in epilepsy through regenerative science
UCB to acquire Neurona Therapeutics, advancing its innovative leadership in epilepsy through regenerative science PR Newswire
15.04.26 - PR Newswire
UCB presents new data demonstrating quality-of-life impacts for epilepsy patients and caregivers at AAN 2026 meeting
UCB presents new data demonstrating quality-​of-life impacts for epilepsy patients and caregivers at AAN 2026 meeting PR Newswire
13.04.26 - PR Newswire
UCB announces new clinical data from its generalized myasthenia gravis (gMG) portfolio at the 2026 American Academy of Neurology (AAN) meeting
UCB announces new clinical data from its generalized myasthenia gravis (gMG) portfolio at the 2026 American Academy of Neurology (AAN) meeting PR Newswire
27.03.26 - PR Newswire
UCB Presents New BIMZELX® (bimekizumab-bkzx) Data at AAD Demonstrating High Rates of Durable and Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis
UCB Presents New BIMZELX® (bimekizumab-​bkzx) Data at AAD Demonstrating High Rates of Durable and Complete Skin Clearance in Moderate-​to-Severe Plaque Psoriasis PR ...
27.03.26 - PR Newswire
UCB Announces New BIMZELX® (bimekizumab-bkzx) Data at AAD Showing Durable Symptom Control Throughout Three Years in Hidradenitis Suppurativa
UCB Announces New BIMZELX® (bimekizumab-​bkzx) Data at AAD Showing Durable Symptom Control Throughout Three Years in Hidradenitis Suppurativa PR Newswire
26.03.26 - PR Newswire
United Community Earns 12th JD Power Award in 17 Years, Ranked #1 for Retail Banking Customer Satisfaction in the Southeast Region
United Community Earns 12th JD Power Award in 17 Years, Ranked #1 for Retail Banking Customer Satisfaction in the Southeast Region PR Newswire
24.03.26 - PR Newswire
UCB Selects Georgia for New U.S. Biologics Manufacturing Facility; ~$5B Economic Impact and ~330 Permanent Jobs
UCB Selects Georgia for New U.S. Biologics Manufacturing Facility; ~$5B Economic Impact and ~330 Permanent Jobs PR Newswire
11.03.26 - PR Newswire
BIMZELX®▼(bimekizumab) superior to SKYRIZI® (risankizumab) in BE BOLD: first head-to-head study in active psoriatic arthritis (PsA) to demonstrate superiority in ACR50
BIMZELX®▼(bimekizumab) superior to SKYRIZI® (risankizumab) in BE BOLD: first head-​to-head study in active psoriatic arthritis (PsA) to demonstrate superiority in ACR50 PR Newswire
08.12.25 - PR Newswire
UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduced countable motor seizure frequency in CDKL5 deficiency disorder
UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduced countable motor seizure frequency in CDKL5 deficiency disorder PR ...
04.12.25 - PR Newswire
UCB shares leading scientific research and advances at American Epilepsy Society Annual Meeting
UCB shares leading scientific research and advances at American Epilepsy Society Annual Meeting PR Newswire
13.11.25 - PR Newswire
United Community Climbs 32 Spots on American Banker's 2025 Best Banks to Work For List
United Community Climbs 32 Spots on American Banker's 2025 Best Banks to Work For List PR Newswire
03.11.25 - PR Newswire
/C O R R E C T I O N -- UCB/
/C O R R E C T I O N -- UCB/ PR Newswire
29.10.25 - PR Newswire
UCB opens applications for 2026 UCB Myasthenia Gravis Scholarship™
UCB opens applications for 2026 UCB Myasthenia Gravis Scholarship™ PR Newswire
29.10.25 - PR Newswire
UCB to unveil new data for RYSTIGGO® (rozanolixizumab-noli) and ZILBRYSQ®(zilucoplan) for gMG at the 2025 AANEM Annual Meeting and MGFA Scientific Session
UCB to unveil new data for RYSTIGGO® (rozanolixizumab-​noli) and ZILBRYSQ®(zilucoplan) for gMG at the 2025 AANEM Annual Meeting and MGFA Scientific Session PR Newswire
25.10.25 - PR Newswire
BIMZELX® (bimekizumab-bkzx) Three-Year Rheumatology Data at ACR 2025 Demonstrated Sustained Inflammation Control in Psoriatic Arthritis and Axial Spondyloarthritis
BIMZELX® (bimekizumab-​bkzx) Three-​Year Rheumatology Data at ACR 2025 Demonstrated Sustained Inflammation Control in Psoriatic Arthritis and Axial Spondyloarthritis PR ...
13.10.25 - PR Newswire
Results published in Neurology highlight a 95% reduction in risk of death with pyrimidine nucleos(t)ide therapy in patients with thymidine kinase 2 deficiency (TK2d)
Results published in Neurology highlight a 95% reduction in risk of death with pyrimidine nucleos(t)ide therapy in patients with thymidine kinase 2 deficiency (TK2d) PR Newswire
17.09.25 - PR Newswire
BIMZELX® (bimekizumab-bkzx) New Three-year Data in Hidradenitis Suppurativa at EADV Showed Sustained Symptom Relief Across Multiple Clinical Endpoints
BIMZELX® (bimekizumab-​bkzx) New Three-​year Data in Hidradenitis Suppurativa at EADV Showed Sustained Symptom Relief Across Multiple Clinical Endpoints PR Newswire
17.09.25 - PR Newswire
BIMZELX® (bimekizumab-bkzx) Data in Moderate-to-Severe Plaque Psoriasis at EADV Showed Complete Skin Clearance Sustained Over Four Years
BIMZELX® (bimekizumab-​bkzx) Data in Moderate-​to-Severe Plaque Psoriasis at EADV Showed Complete Skin Clearance Sustained Over Four Years PR Newswire

Newssuche

Videos

newspaper
26.04.26
Big Fish Strategy Einführung
Strategie-​Paket inklusive Live-​Webinar am 3.5., Videoaufzeichnung, Unterlagen und Nachbetreuung JETZT ... Mehr »
Anzeige

Aktie im Fokus

Mit Graphen gegen jede Abwehr
Plaid Technologies
0,396 €
+7,03%
Plaid Technologies Chart
Die Zukunft der Drohnen ist da
Mehr zur Aktie »